GlassScriptPhysician profile
Ralph I Silverman
NPI 1356337695
$1,569.11
in general payments reported to CMS, 2019-2025
12 companies · $82.95 in 2025
The $82.95 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $117 · 2021: $284 · 2022: $270 · 2023: $238 · 2025: $82.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $333.83 | 2021-2023 | Verquvo |
| Janssen Biotech, INC. | $256.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $212.71 | 2019-2023 | |
| Edwards Lifesciences Corporation | $164.10 | 2019-2023 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $140.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $118.62 | 2019-2022 | |
| Pfizer INC. | $107.60 | 2021-2023 | |
| Boston Scientific Corporation | $105.19 | 2023-2025 | Watchman Flx, Watchman Access System |
| Amarin Pharma, INC. | $40.36 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $35.39 | 2022-2023 | Eliquis |
| Dentsply Ih INC. | $31.33 | 2019 | |
| Acarix USA INC. | $23.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.